主页 > 医学文档 >
【Breaking News】-钟南山院士研制siRNA药物治疗SAR
这项课题名为“防治ＳＡＲＳ疾病特效ｓｉＲＮＡ（小分子干扰核糖核酸）研究”，由广东防治非典科技攻关协作组主持，中国工程院院士钟南山任首席顾问、著名生物技术专家李宝健教授及旅美生物医药专家陆阳博士作为课题组负责人，自两年前开始进行。
钟南山介绍说，小干扰核酸是目前国际上最先进的一种生物医药技术，其原理是可令某一或某些病毒的特定基因“沉默”并失去功能，或将ＲＮＡ病毒的基因组分解，而被分解的片段成为新的力量去消灭其它病毒。课题组的科学家们针对ＳＡＲＳ冠状病毒基因组设计小干扰核酸药物，采用中国医学科学院动物所建立的恒河猴ＳＡＲＳ冠状病毒感染和实验模型，进行抗病毒感染试验，并在世界上首次获得成功。科学家们选取了5组共20只恒河猴进行实验。接受药物治疗的猴子病毒复制量减少了75％，病猴肺部的损伤明显减轻，而且随剂量增加，疗效进一步改善，无副作用。而在感染前就接受小干扰核酸药物的猴子，发病症状最轻，体温上升和肺部损伤病变均明显减轻。
这一突破性的科技成果所形成的科学论文，将发表在9月号的世界顶级科学刊物《自然医学》杂志上，网络版已于8月21日公布。此成果引起国际学术界的重视，《自然医学》对该项科技成果给予了极高的评价，指出：“这项工作对防治将来可能发生的冠状病毒爆发有重要的影响，而且标志了在应用小干扰核酸技术进行新药开发领域中的一个重要贡献”。
钟南山表示，小干扰核酸技术还将在人类对付其它各种抗病毒性传染病如肝炎、艾滋病等，还有恶性肿瘤和老年病等疑难病症的治疗方面发挥强有力的作用。这项研究取得的重要进展，不仅为人类防治ＳＡＲＳ的ｓｉＲＮＡ药物进入人体临床试验阶段打下了坚实基础，也标志着课题组的技术水平在研究开发siＲＮＡ药物领域走在了国际领先行列。
文章地址：http://www.nature.com/nm/journal/vaop/ncurrent/abs/nm1280.html
NATURE MEDICINE ISSN：1078-8956 IF=31.223 Published online: 21 August 2005; | doi:10.1038/nm1280
[Title] Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque
Bao-jian Li1, 2, 7, Qingquan Tang3, 7, Du Cheng2, 7, Chuan Qin4, 7, Frank Y Xie2, 3, Qiang Wei4, Jun Xu3, Yijia Liu3, Bo-jian Zheng5, Martin C Woodle3, Nanshan Zhong6 & Patrick Y Lu3
1 Biotechnology Research Center of Sun Yatsen University, and Key Laboratory of Gene Engineering of Ministry of Education of the State, Guangzhou, China.
2 Guangzhou Top Genomics, Ltd., Guangzhou, China.
3 Intradigm Corporation, 12115 K Parklawn Drive, Rockville, Maryland 20852, USA.
4 Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
5 Department of Pathology, University of Hong Kong, Hong Kong, China.
6 Guangzhou Institute of Respiratory Diseases, Guangzhou, China.
7 These authors contributed equally to this work.
Correspondence should be addressed to Patrick Y Lu patricklu@intradigm.com or Nanshan Zhong nanshan@vip.163.com
[Abstract] Development of therapeutic agents for severe acute respiratory syndrome (SARS) viral infection using short interfering RNA (siRNA) inhibitors exemplifies a powerful new means to combat emerging infectious diseases. Potent siRNA inhibitors of SARS coronavirus (SCV) in vitro were further evaluated for efficacy and safety in a rhesus macaque (Macaca mulatta) SARS model using clinically viable delivery while comparing three dosing regimens. Observations of SARS-like symptoms, measurements of SCV RNA presence and lung histopathology and immunohistochemistry consistently showed siRNA-mediated anti-SARS efficacy by either prophylactic or therapeutic regimens. The siRNAs used provided relief from SCV infection−induced fever, diminished SCV viral levels and reduced acute diffuse alveoli damage. The 10−40 mg/kg accumulated dosages of siRNA did not show any sign of siRNA-induced toxicity. These results suggest that a clinical investigation is warranted and illustrate the prospects for siRNA to enable a massive reduction in development time for new targeted therapeutic agents. 他们怎么这么厉害 有没有全文啊？ 可喜！
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-25 05:16
医学,生命科学网